SCHEMBL932145

SCHEMBL932145

COc1c(C)cc(C#N)cc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 1/20 0.44
AR P10275 3/20 0.40
TTR P02766 1/20 0.38
ALB P02768 1/20 0.38
RECQL P46063 1/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP2A6 P11509 1/20 0.37
ACHE P22303 1/20 0.36
ABCC3 O15438 1/20 0.35
ESR1 P03372 1/20 0.35
CYP1A2 P05177 1/20 0.35
PGR P06401 1/20 0.35
CHRM2 P08172 1/20 0.35
ABCB1 P08183 1/20 0.35
CYP3A4 P08684 1/20 0.35
ADRA2A P08913 1/20 0.35
CYP2D6 P10635 1/20 0.35
CHRM1 P11229 1/20 0.35
CYP2C9 P11712 1/20 0.35
DRD1 P21728 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL523729 0.87 AR (0.46) GPR35ARACHECYP3A4CACNA1G
SCHEMBL16077413 0.81 AR (0.42) GPR35ARALDH1A1PGR
SCHEMBL28929310 0.80 ACHE (0.39) ALDH1A1ACHECYP3A4
SCHEMBL27496792 0.80 GPR35 (0.49) GPR35ALDH1A1
SCHEMBL22030024 0.78 SQOR (0.44) GPR35ARALDH1A1CYP1A2CYP2C9
SCHEMBL7664968 0.76 ALDH1A1 (0.40) ALDH1A1ACHECYP3A4
SCHEMBL509507 0.76 ACHE (0.52) GPR35ARALDH1A1ACHECYP1A2
SCHEMBL9127896 0.76 ALDH1A1 (0.36) ALDH1A1ACHECYP3A4
SCHEMBL2088423 0.76 GPR35 (0.44) GPR35ARTTRALBALDH1A1
SCHEMBL13480569 0.76 GPR35 (0.41) GPR35TTRALBALDH1A1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228872-A1 NANOPARTICLE-CONTAINING FILM, LIGHT-EMITTING ELEMENT, PRODUCTION METHOD FOR NANOPARTICLE-CONTAINING FILM SHARP KABUSHIKI KAISHA (JP) 2024-07-11 US disclosed
US-20240228872-A1 NANOPARTICLE-CONTAINING FILM, LIGHT-EMITTING ELEMENT, PRODUCTION METHOD FOR NANOPARTICLE-CONTAINING FILM SHARP KABUSHIKI KAISHA (JP) 2024-07-11 US disclosed
US-20240228872-A1 NANOPARTICLE-CONTAINING FILM, LIGHT-EMITTING ELEMENT, PRODUCTION METHOD FOR NANOPARTICLE-CONTAINING FILM SHARP KABUSHIKI KAISHA (JP) 2024-07-11 US disclosed
EP-3676252-B1 DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE CHULABHORN FOUND (TH) 2023-11-29 EP disclosed
WO-2022254601-A1 NANOPARTICLE-CONTAINING FILM, LIGHT-EMITTING ELEMENT, PRODUCTION METHOD FOR NANOPARTICLE-CONTAINING FILM シャープ株式会社 2022-12-08 WO disclosed
US-10889566-B2 Derivatives and composition of quinoline and naphthyridine CHULABHORN FOUNDATION (TH) 2021-01-12 US disclosed
US-20200223820-A1 DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE CHULABHORN FOUNDATION (TH) 2020-07-16 US disclosed
EP-3184171-B1 PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS CHEVRON PHILLIPS CHEMICAL CO LP (US) 2019-03-20 EP disclosed
EP-3184171-A1 PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS Chevron Phillips Chemical Company LP (US) 2017-06-28 EP disclosed
EP-2519532-B1 PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS CHEVRON PHILLIPS CHEMICAL CO LP (US) 2017-03-08 EP disclosed
WO-2011002407-A1 NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA ASTRAZENECA AB (SE) 2011-01-06 WO disclosed
US-7259229-B2 Electroactive fluorene polymers having perfluoralkyl groups, process for preparing such polymers and devices made with such polymers E.I. DU PONT DE NEMOURS AND COMPANY (US) 2007-08-21 US disclosed
US-7259229-B2 Electroactive fluorene polymers having perfluoralkyl groups, process for preparing such polymers and devices made with such polymers E.I. DU PONT DE NEMOURS AND COMPANY (US) 2007-08-21 US disclosed
US-7230070-B2 Electroactive fluorene copolymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-06-12 US disclosed
US-7220820-B2 Electroactive fluorene copolymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-05-22 US disclosed
US-7214763-B2 Electroactive fluorene copolymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-05-08 US disclosed
US-7211643-B2 Electroactive fluorene copolymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-05-01 US disclosed
US-7183365-B2 Electroactive fluorene polymers having perfluoroalkyl groups, process for preparing such polymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-02-27 US disclosed
US-7183366-B2 Aromatic copolymers from dihalofluorene compounds and another dihalo- or diborono- aromatic monomers; organic electroluminescent polymers for use in light-emitting diodes E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-02-27 US disclosed
WO-2007020502-A2 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PHARMACIA & UPJOHN COMPANY LLC (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10889566-B2 Derivatives and composition of quinoline and naphthyridine MCL1, TOP1, NQO2 GPR35 4308/4885AR 2555/4885TTR 4204/4885
US-20200223820-A1 DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE C1R, CBR3, CBR1 GPR35 2239/4885AR 532/4885TTR 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.